TMC5

Across TCGA pan-cancer cohorts, TMC5 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated TMC5 data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMC5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMC5 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LUAD, KIRC, and LIHC are the cancer types where TMC5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	IV	0.194	0.734	<.001	40	view →
KIRC	OS	Median	All	0.218	0.812	<.001	32	view →
LIHC	OS	Median	All	0.109	0.779	<.001	18	view →
UCEC	DFS	Median	All	0.944	0.607	.005	18	view →
COAD	OS	Median	III,IV	0.056	0.783	<.001	17	view →
SKCM	OS	Median	II,III,IV	0.928	0.813	.005	9	view →
GBM	DFS	Median	All	0.043	0.243	.003	6	view →
OV	DFS	Median	All	0.132	0.541	.001	6	view →
LUSC	DFS	Median	III,IV	0.079	0.751	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

TMC5–LUAD (DFS)

Open the LUAD breakdown →